Product Dossier
ZIAGEN
Product Dossier for ZIAGEN (abacavir, ViiV Healthcare). ARTG record, PBS listing, PBAC outcomes — compiled by arcimedes.
- Sponsor: ViiV Healthcare
- Active ingredient: abacavir
- Therapeutic area: Infectious Disease
- Related brand: TRIUMEQ
- Related brand: KIVEXA
- Related brand: ABALAMID HETERO
- Same area: RETROVIR
- Same area: Savacol Antiseptic Mouth & Throat Rinse
What it is
ZIAGEN is abacavir sulfate, available as a 300 mg tablet or a 20 mg/mL oral solution.
PBS listing
ZIAGEN tablets (300 mg) are listed on the PBS with streamlined restrictions at an ex-manufacturer price of A$178.16. The oral solution (20 mg/mL, 240 mL) is listed on the PBS with authority required restrictions at an ex-manufacturer price of A$66.72.
Regulatory history
ZIAGEN was first registered on the ARTG on 9 June 1999, with both the 300 mg tablet and 20 mg/mL oral solution formulations listed simultaneously.